Differentiation of clear from non-clear cell renal cell carcinoma using CT washout formula

被引:0
|
作者
Kopp, Ryan P. [1 ,2 ]
Aganovic, Lejla [3 ,4 ]
Palazzi, Kerrin L. [1 ]
Cassidy, Fiona H. [3 ,4 ]
Sakamoto, Kyoko [1 ,2 ]
Derweesh, Ithaar H. [1 ,2 ]
机构
[1] Univ Calif San Diego, Sch Med, Dept Surg, Div Urol, La Jolla, CA 92093 USA
[2] San Diego Vet Adm Med Ctr, Surg Serv, La Jolla, CA USA
[3] Univ Calif San Diego, Sch Med, Dept Radiol, La Jolla, CA 92093 USA
[4] San Diego Vet Adm Med Ctr, Serv Radiol, La Jolla, CA USA
关键词
carcinoma; renal cell; computerized tomography; diagnosis; enhancement; histology; Hounsfield unit; PATHOLOGICAL FEATURES; CORTICAL TUMORS; CORE BIOPSY; MASSES; SUNITINIB; PAPILLARY; EFFICACY; CM;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: To further elucidate potential patterns of contrast enhancement for renal neoplasm subtypes, we investigated utility of contrast washout formula to differentiate renal tumor histology after multiphase computerized tomography (CT). Materials and methods: Single center retrospective cohort study of 163 patients with multiphase CT for renal masses obtained October 2007 to July 2012. Pathology confirmed clear cell (CC-RCC; n = 92), papillary (Pa-RCC; n = 43), chromophobe (Ch-RCC; n = 6), oncocytoma (OC; n = 11), or angiomyolipoma (AML; n = 11) histology. Two radiologists in consensus and blinded to histology recorded tumor size, morphology, and attenuation measurements in Hounsfield Units (HU). Data were analyzed between subgroups based on histology. Enhancement washout of the tumor was calculated by the formula (Mass nephrographic HU-Mass delayed HU)/(Mass nephrographic HU-Mass non-contrast HU) and used to calculate sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Results: Tumor size was largest among CC-RCC (p < 0.001). Homogeneous composition was more common among Pa-RCC and Ch-RCC (p < 0.001). Median washout for Ch-RCC (0.27) was significantly different from that of OC (0.54, p = 0.05). Overall 25 (15.3%) of tumors had washout < 0. Tumors with washout value < 0 were Pa-RCC 24/43 (56%), and Ch-RCC 1/6 (14%). Washout value < 0 had a specificity of 99.2% for Pa-RCC and 100% for non-CC-RCC. Washout value >= 0 had a sensitivity and NPV of 100% for CC-RCC, OC, and AML. Washout value 0 had a specificity of 35.2% and a PPV of 66.7% for CC-RCC. Conclusions: Enhancement washout value < 0 is highly specific for Pa-RCC and non-CC-RCC. Washout value 0 is highly sensitive for CC-RCC, OC, and AML while there was a significant difference in median washout between OC and Ch-RCC. Further prospective investigation is requisite to confirm these findings.
引用
收藏
页码:6790 / 6797
页数:8
相关论文
共 50 条
  • [41] Loss of PBRMI and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma
    Ho, Thai H.
    Kapur, Payal
    Joseph, Richard W.
    Serie, Daniel J.
    Eckel-Passow, Jeanette E.
    Parasramka, Mansi
    Cheville, John C.
    Wu, Kevin J.
    Frenkel, Eugene
    Rakheja, Dinesh
    Stefanius, Karoliina
    Brugarolas, James
    Parker, Alexander S.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (01) : 23.e9 - 23.e14
  • [42] Renal cell carcinoma with non-clear cell histology or sarcomatoid differentiation: recent insight in an unmet clinical need
    Donskov, Frede
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (02)
  • [43] The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature
    Ventriglia, Jole
    Passarelli, Anna
    Pisano, Carmela
    Cecere, Sabrina Chiara
    Rossetti, Sabrina
    Feroce, Florinda
    Forte, Miriam
    Casartelli, Chiara
    Tambaro, Rosa
    Pignata, Sandro
    Perversi, Fabio
    Di Napoli, Marilena
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 188
  • [44] Clinicopathological characteristics and prognosis of metastatic non-clear cell renal cell carcinoma.
    Wu, Jie
    Cui, Hong-Lei
    Shi, Hongzhe
    Guan, Youyan
    Bi, Xin-Gang
    Zhou, Aiping
    Shou, Jianzhong
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [45] Clear cell and non-clear cell renal cell carcinoma in young adults: clinicopathological features, survival outcomes and prognostic factors
    Xue, Zixuan
    Tang, Shiying
    Ou, Junyong
    Fang, Yangyi
    Qiu, Min
    Hong, Kai
    Tian, Xiaojun
    Zhang, Hongxian
    Liu, Cheng
    Ma, Lulin
    Zhang, Shudong
    WORLD JOURNAL OF UROLOGY, 2024, 42 (01)
  • [46] Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities
    Zarrabi, Kevin
    Walzer, Emily
    Zibelman, Matthew
    CANCERS, 2021, 13 (15)
  • [47] Adjuvant Therapy for Non-Clear Cell Renal Cell Carcinoma-The Ascent Continues
    Brown, Jacqueline T.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [48] Differentiation of Clear Cell and Non-clear-cell Renal Cell Carcinoma through CT-based Radiomics Models and Nomogram
    Cheng, Delu
    Abudikeranmu, Yeerxiati
    Tuerdi, Batuer
    CURRENT MEDICAL IMAGING, 2023, 19 (09) : 1005 - 1017
  • [49] Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022
    Benjamin L. Maughan
    Current Oncology Reports, 2022, 24 : 1201 - 1208
  • [50] Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature
    John, Alexius
    Spain, Lavinia
    Hamid, Anis A.
    CURRENT ONCOLOGY, 2023, 30 (01) : 923 - 937